Close X
Thursday, November 28, 2024
ADVT 
Health

Forget injection, pills to cure hardest-to-treat hepatitis C

Darpan News Desk IANS, 28 Jul, 2014 07:26 AM
    On this World Hepatitis Day, there's good news for patients, particularly from India, for those suffering from hepatitis C.
     
    Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two new studies.
     
    Both studies focused on hepatitis C genotype 1, one of the most difficult to treat.
     
    On Monday, there were reports that the Indian government was importing Rs.1 crore ($166,000) worth one of the drugs - sofosbuvir. Each pill costs $1,000 or $84,000 for a 12-week course.
     
    Around 150 million people worldwide have chronic hepatitis C virus (HCV) infection, a condition that is a major cause of liver cirrhosis and liver cancer.
     
    Until recently, the standard of care for chronic HCV genotype 1 involved a combination of three drugs; ribavirin (RBV), pegylated interferon (PEG) and a protease inhibitor, which together inhibit viral replication and enhance the body's immune response to eradicate the virus.
     
    These drugs can place a substantial burden on the patient, with complicated injection and pill regimens, which can involve up to 18 tablets a day and last for up to a year, and can also cause severe side effects including anaemia and depression.
     
    Direct-acting antiviral agents (DAAs) provide new opportunities for treatment whilst reducing the need for interferon and ribavirin and their potential side effects, one of these two studies showed.
     
    Researchers assigned 645 patients with HCV genotype 1b from 18 countries to receive a 6-month course of treatment with a pair of oral DAAs asunaprevir and daclatasvir.
     
    With this regimen, 90 percent of previously untreated patients and 82 percent who were intolerant of, or who had been treated unsuccessfully using standard regimens, were cured.
     
    "This new all-oral interferon and ribavirin-free combination could provide a more effective, safer, shorter, and simpler treatment option for those traditionally hard-to-cure patients with cirrhosis or those who have failed to respond to existing therapies," said professor Michael Manns from Hannover Medical School in Germany.
     
    In a separate study, a team of researchers led by professor Eric Lawitz from University of Texas Health Science Center in San Antonio, assigned 167 individuals with HCV genotype 1a and 1b to receive a 12-week or 24-week course of once-daily sofosbuvir plus simeprevir with or without ribavirin.
     
    After just 12 weeks of treatment without ribavirin, 93 percent of participants (including those with cirrhosis and previous non-responders to interferon-based treatment) were cured - with no detectable virus in their blood three months after treatment had stopped.
     
    Both the studies appeared in the journal The Lancet.

    MORE Health ARTICLES

    Walking speed may detect Alzheimer's risk

    Walking speed may detect Alzheimer's risk
    How fast people walk and whether they have memory complaints can help predict dementia early, researchers have found....

    Walking speed may detect Alzheimer's risk

    Night lights can wake up breast cancer cells

    Night lights can wake up breast cancer cells
    Sleeping at night with the lights on can not only add to your energy consumption, but also wake up breast cancer cells, a study suggests....

    Night lights can wake up breast cancer cells

    Virus linked to obesity and diabetes found

    Virus linked to obesity and diabetes found
    Biologists have discovered an extremely widespread virus that could be as old as humans and could play a major role in obesity and diabetes...

    Virus linked to obesity and diabetes found

    Men in shift work at higher type 2 diabetes risk: Study

    Men in shift work at higher type 2 diabetes risk: Study
    The reasons for this finding are not clear, say the authors, but suggest that men working shift patterns might need to pay more attention to the possible health...

    Men in shift work at higher type 2 diabetes risk: Study

    How malaria parasite resists key trial drug

    How malaria parasite resists key trial drug
    Researchers have uncovered a way the malaria parasite becomes resistant to a key clinical trial drug....

    How malaria parasite resists key trial drug

    Immune response to injury may damage brain: Study

    Immune response to injury may damage brain: Study
    Can our immune system trigger memory impairment and cognitive dysfunction leading to chronic neurological diseases? Researchers at Cleveland Clinic in Ohio believe so....

    Immune response to injury may damage brain: Study